September 16, 20240 citations

Figure S1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

SLSun Min Lim TFToshio Fujino CKChulwon Kim

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Supplementary Figure 1. Growth inhibition by BBT-176 with and without cetuximab in EGFR 19Del and EGFR L858R-derived mutants. Abbreviation: N/E, not evaluable.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Lim et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523ae2 https://doi.org/10.1158/1078-0432.27032026.v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
2Figure S4 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
3Figure S10 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
4Figure S3 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
5Figure S2 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo